Physician profile
Ron Creque
NPI 1194717397
$13,632.61
in general payments reported to CMS, 2019-2025
60 companies · $1,800 in 2025
The $1,800 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $1,617 · 2021: $2,412 · 2022: $2,453 · 2023: $1,971 · 2024: $1,907 · 2025: $1,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,678.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,693.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,544.72 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,272.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,090.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $792.18 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $716.46 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $638.80 | 2019-2025 | Trintellix |
| Amgen INC. | $547.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $536.58 | 2019-2022 | |
| Novo Nordisk INC | $498.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $467.61 | 2019-2022 | |
| Astellas Pharma US INC | $426.98 | 2019-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $406.88 | 2020-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $309.38 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $281.97 | 2019-2025 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Creque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.